Check for updates

OPEN ACCESS

EDITED BY Qi Zhao, University of Science and Technology Liaoning, China

REVIEWED BY Georgia Damoraki, National and Kapodistrian University of Athens, Greece Bo-Wei Zhao, Chinese Academy of Sciences (CAS), China Yuchen Li, Stanford University, United States

*CORRESPONDENCE Han Luo ⊠ luohan-hx@scu.edu.cn Zhi-Hui Li ⊠ rockoliver@vip.sina.com Yuwei Zhang ⊠ doczhangyw@scu.edu.cn

[†]These authors have contributed equally to this work

RECEIVED 13 December 2023 ACCEPTED 29 January 2024 PUBLISHED 26 February 2024

CITATION

Zhang X, Li P-H, Wang D, Li H, Kong X, Zhang G, Zhao Y, Liu J, Wu W, Zhang Y, Li Z-H and Luo H (2024) Causal effect of gut microbiota of *Defluviitaleaceae* on the clinical pathway of "Influenza–Subacute Thyroiditis–Hypothyroidism". *Front. Microbiol.* 15:1354989. doi: 10.3389/fmicb.2024.1354989

COPYRIGHT

© 2024 Zhang, Li, Wang, Li, Kong, Zhang, Zhao, Liu, Wu, Zhang, Li and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Causal effect of gut microbiota of *Defluviitaleaceae* on the clinical pathway of "Influenza–Subacute Thyroiditis–Hypothyroidism"

Xin Zhang^{1,2†}, Pei-Heng Li^{3†}, Dongyue Wang^{4†}, Hancong Li³, Xiangyu Kong³, Gongshuang Zhang³, Yue Zhao³, Jiaye Liu³, Wenshuang Wu³, Yuwei Zhang^{5,6*}, Zhi-Hui Li^{3*} and Han Luo^{3,7*}

¹Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China, ²Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China, ³Division of Thyroid Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China, ⁴Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, China, ⁵Department of Endocrinology and Metabolism, West China Hospital of Sichuan University, Chengdu, China, ⁶Center for Diabetes and Metabolism Research, West China Hospital of Sichuan University, Chengdu, China, ⁷Department of Laboratory Medicine/Research Centre of Clinical Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Introduction: Hypothyroidism has been found to be influenced by gut microbiota. However, it remains unclear which a taxon of gut microbiota plays a key role in this function. Identifying the key bacteria affects hypothyroidism and through what mechanism will be helpful for the prevention of hypothyroidism through specific clinical pathways.

Materials and methods: In Study A, 35 families and 130 genera of gut microbiota are used as exposures, with hypothyroidism as the outcome. The causal effect of the gut microbiota on hypothyroidism is estimated through two-sample Mendelian randomization. Combining the results of the two taxonomical levels, key taxa are selected, which in Study B are investigated for their causal association with multiple generally admitted causes of hypothyroidism and their more upstream factors. For validating and revealing the potential mechanism, enrichment analyses of the related genes and interacting transcription factors were performed.

Results: In Study A, *Defluviitaleaceae* (OR: 0.043, 95% CI: 0.005–0.363, P = 0.018)/*Defluviitaleaceae_UCG_011* (OR: 0.385, 95% CI: 0.172–0.865, P = 0.021) are significantly causally associated with hypothyroidism at both taxonomical levels. In Study B, *Defluviitaleaceae* family and *Defluviitaleaceae_UCG_011* genus show the causal association with decreased thyroiditis (Family: OR: 0.174, 95% CI: 0.046–0.653, P = 0.029; Genus: OR: 0.139, 95% CI: 0.029–0.664, P = 0.043), decreased subacute thyroiditis (Family: OR: 0.028, 95% CI: 0.004–0.213, P = 0.007; Genus: OR: 0.018, 95% CI: 0.002–0.194, P = 0.013), decreased influenza (Family: OR: 0.818, 95% CI: 0.676–0.989, P = 0.038; Genus: OR: 0.792, 95% CI: 0.644–0.974, P = 0.027), and increased anti-influenza H3N2 IgG levels (Family: OR: 1.934, 95% CI: 1.123–3.332, P = 0.017; Genus: OR: 1.675, 95% CI: 0.953–2.943, P = 0.073). The results of the enrichment analysis are consistent with the findings and the suggested possible mechanisms.

Conclusion: *Defluviitaleaceae* of the gut microbiota displays the probability of causally inhibiting the clinical pathway of "Influenza–Subacute Thyroiditis– Hypothyroidism" and acts as the potential probiotics to prevent influenza, subacute thyroiditis, and hypothyroidism.

KEYWORDS

gut microbiota, hypothyroidism, influenza, Mendelian randomization, subacute thyroiditis



Introduction

Hypothyroidism is defined as the condition of thyroid hormone deficiency. The prevalence of hypothyroidism is approximately 3%-7% (Hollowell et al., 2002; Garmendia Madariaga et al., 2014). Patients can suffer from fatigue, lethargy, cold intolerance, weight gain, constipation, change in voice, and dry skin. The clinical manifestations range from life-threatening conditions to no symptoms at all (Chaker et al., 2017). Hypothyroidism has also been found to be associated with heart diseases, such as the coronary artery disease and heart failure, and cause higher mortality (Vanhaelst et al., 1967; Rodondi et al., 2010; Gencer et al., 2012). Hypothyroidism can be classified into primary hypothyroidism, central hypothyroidism, and peripheral hypothyroidism. Among them, thyroiditis, such as chronic autoimmune thyroiditis and subacute thyroiditis, are the common causes (Chaker et al., 2017). The standard treatment of hypothyroidism is through thyroid hormone replacement therapy with levothyroxine. However, some patients fail to improve their quality of life after the treatment (Hegedüs et al., 2022). Thus, it is important to understand the cause of hypothyroidism and identify the potential therapies to prevent and treat hypothyroidism.

Human gut microbiota is composed of trillions of microorganisms, including bacteria, fungi, viruses, and archaea (Eckburg et al., 2005). As an essential component in human body, gut microbiota takes part in the digestion of nutrients, the metabolism of several drugs, and host immune system development, which are pivotal for human body homeostasis (Round and Mazmanian, 2009; Dodd et al., 2017). The development of 16S rRNA gene and metagenome sequencing have led to studies on the interactions between microbiota and humans into a new era (Gill et al., 2006; Qin et al., 2010). Numerous studies have been performed to explore the relationship between intestinal microbiota and diseases, such as gastrointestinal diseases, psychiatric diseases, metabolic diseases, and autoimmune diseases (Tlaskalová-Hogenová et al., 2011; Chen et al., 2016; Vitale et al., 2021). Some studies have indicated the association between gut microbiota and thyroid diseases, along with the concept of "thyroid-gut-axis" (Lerner et al., 2017; Fröhlich and Wahl, 2019; Jiang et al., 2022; Virili et al., 2023). However, whether the alteration of microbiota is the cause of thyroid diseases cannot be determined. Taking advantage of Mendelian randomization (MR), the causal relationship between exposure and outcome can be ascertained. Compared with traditional observational studies, MR utilizes genetic variations to infer the causal connection, which is more reliable (Yao et al., 2022).

This study is designed determine the causal to effect gut microbiota on hypothyroidism and further explore how the screened taxon of microbiota causes hypothyroidism.

Abbreviations: CI, Confidence interval; GWAS, Genome-wide association studies; IV, Instrument variable; IVW, Inverse varianceweighted; MR, Mendelian randomization; OR, Odds ratio; SNP, Single nucleotide polymorphism.

Materials and methods

Study design

This study is designed to determine the causal effect of gut microbiota on hypothyroidism and further explore through which pathway the screened taxon of microbiota causes hypothyroidism. MR analyses (Burgess and Thompson, 2021) are used to provide evidence for the causal association between microbiota and steps in the clinical pathway to hypothyroidism.

Study A is designed to screen the potential taxa of the gut microbiota that are causally related to hypothyroidism (Figure 1A). In Study A, two families and genera of gut microbiota that can causally affect the occurrence of hypothyroidism are investigated. Since the rigorous correction for multiple comparisons might neglect potential taxa that are causally associated with hypothyroidism, multiple testing is not performed in Study A. Screening is done according to three criteria. The first criterion is significant at both family and genus levels, which can increase the robustness and reliability of the results of the selected microbiota. Although it might wrongly remove some potentially valuable microbiota, it can better make sequent results correct. The second criterion is better to be validated by multiple MR methods. Each MR method has its own strengths. With significant results of more MR methods, the sequent analyses become more reliable. The third criterion is, if there are probiotics and harmful microbiota screened at the same time, the probiotics will be chosen as the final candidate target. Because the supplement of a bacteria is easier and more economical than targeting a bacterium, the findings will have higher clinical values. The screened key taxon of the gut microbiota is then used in Study B to determine more specific mechanisms.

In Study B, the screened "key taxon" is used to investigate whether it has a causal effect on known causative factors of hypothyroidism with MR analyses (Figure 1B). Then, the former known causative factors are further investigated to identify a causally affected clinical pathway. By confirming the linear causal effect of "key taxon" at each step of the known clinical pathway, the application potential of the identified taxon of gut microbiota can be proven.

Data source

All data used in this study are summary-level data of genomewide association studies (GWAS). The source of all data is summarized in Supplementary Table S1.

The data of gut microbiota are available from the MiBioGen database (https://mibiogen.gcc.rug.nl/), which was provided by Kurilshikov et al. (2021). These comprehensive GWAS data of gut microbiota were collected from a pool of 18,340 individuals from 24 cohorts. The data of 165 taxa (including 35 families and 130 genera) are finally used in the present study. The details about the measurement methods can be checked in previously published studies by Kurilshikov et al. (2021). Supplementary Table S2 lists all the taxa of gut microbiota used in this study (in the column "exposure").

Fecal samples were collected from 18,340 people, the majority of whom are Europeans with a median age of approximately 55 years. After fecal sample collection from each cohort, DNA purification kits were used to extract the DNA. The MiSeq technology was used for DNA sequencing in most cohorts, while the HiSeq2500 technology was used for one cohort. Due to differences in the 16S rRNA gene domains among the cohorts, the author directly mapped the reads to the SILVA ribosomal RNA database for taxonomic classification. A cutoff posterior probability of 0.8 was applied at each taxonomic level to assign reads to their respective taxa. This posterior cutoff probability was assessed independently for each taxonomic level. Only taxa present in over 10% of the samples within each cohort were left. For the comprehensive mapping of multi-cohort Quantitative Trait Loci, the study-wide criteria were an effective sample size of a minimum of 3,000 samples and presence in at least three cohorts. The single nucleotide polymorphism (SNP) panels of cohorts were mainly provided by Illumina and Affymetrix. After quality control, SNPs strongly associated with one of the different taxa (P < 0.0001), as well as their corresponding positions, alleles, regression results, and sample size, all of which were recorded and uploaded to the MiBioGen database used in this study.

The outcome variables are all collected from the IEU OpenGWAS project (https://gwas.mrcieu.ac.uk/), which was built by the University of Bristol, and contains summary-level GWAS data from multiple databases. For example, the outcome variable of Study A, hypothyroidism, is derived from UK Biobank but downloaded from IEU OpenGWAS project.

In the investigation of factors contributing to hypothyroidism, the majority of data are derived from FinnGen database, which is built by the University of Helsinki, since it divided hypothyroidism into different subtypes, such as autoimmune hypothyroidism and hypothyroidism due to medicaments and other exogenous factors. However, in the exploration of infectious variables related to subacute thyroiditis, there are no data about coxsackievirus and adenovirus in the FinnGen database. Instead, the summary-level GWAS data of coxsackievirus and adenovirus receptor provided by Sun et al. (2018) are used. Details can be checked in each source database (Supplementary Table S1).

Selection of instrument variables

The instrument variable (IV) selection is done according to the standardized processes of MR analyses using *P*-value threshold and linkage disequilibrium (LD) clumping. To obtain the adequate number of genetic variations as IVs and retain IVs strongly associated with each taxon of gut microbiota, the significant threshold is finally set at 1×10^{-5} , which is also a common threshold in many high-quality MR studies of gut microbiota (Li et al., 2022; Song et al., 2023). Then, SNPs with LD are also removed using a threshold of $r^2 < 0.001$ and a maximum distance of 10,000 kb. Finally, 2,105 independent SNPs associated with 165 bacterial traits are identified as IVs.



Mendelian randomization analysis methods

This study adhered to the three core assumptions of MR, as outlined by Bowden and Vansteelandt (2011): (1) the IVs are strongly associated with the taxa of gut microbiota, (2) IVs are independent of confounders affecting outcome variables, and (3) the IVs affect the outcome variable solely through the exposure and not via alternative pathways. The first assumption is met in the selection of SNPs, while the last two are assessed by pleiotropy tests.

In this study, five MR analytical methods are used, namely, inverse variance-weighted (IVW), MR Egger, weighted median, weighted mode, and simple median. IVW is the method with the greatest statistical power but biased if there is horizontal pleiotropy. On the contrary, the MR Egger method is robust to horizontal pleiotropy. The weighted median method is more robust to outliers than IVW and useful when significant result is found in the heterogeneity test. The weighted mode and simple median methods are supplementary to the weighted median method. Therefore, the primary methods of MR analyses are IVW when no horizontal pleiotropy or heterogeneity is found, MR Egger when there is horizontal pleiotropy, and weighted median when there is heterogeneity but no horizontal pleiotropy (Burgess and Thompson, 2021). The Supplementary material contains more detailed introduction of these analytical methods of MR and the way and rationale for the method selection.

MR analysis relies on Mendel's laws of inheritance and instrumental variable estimation methods, which are designed to calculate causal effects in the presence of unobserved confounding (Sanderson et al., 2022). To address potential confounders, heterogeneity and pleiotropy have to be estimated and used for the selection of the robust MR methods. Heterogeneity refers to differences and outliers in SNP-specific causal estimates. Cochran's Q statistic is calculated to evaluate heterogeneity in this study, which is a weighted sum of the squared distances of the SNP-specific causal estimates from the overall IVW estimate. The term pleiotropy is sometimes used interchangeably with "horizontal pleiotropy," while "mediation" is sometimes called "vertical pleiotropy." Horizontal pleiotropy indicates that IVs can affect outcomes through covariate rather than only through the exposure, while vertical pleiotropy indicates exposure affect outcome via the covariate. Horizontal pleiotropy is detected by the MR Egger method, while horizontal pleiotropy can also be detected robustly.

In addition, sensitivity analyses with the leave-one-out method are performed to assess the reliability, stability, and robustness of the causal estimates, specifically investigating whether the results were disproportionately influenced by any individual SNP. The calculation of all analyses was done with the "TwoSampleMR" package (version 0.5.6) on R (version 4.2.2). The results of MR analyses are presented with odds ratio (OR) and confidence intervals (CIs). With a significance level below P of < 0.05, it can be concluded that there might be a causal relationship.

Exploration of related mechanisms with enrichment analysis

Since the MR analysis of clinical outcomes does not reveal the molecular mechanisms, we attempted to carry out enrichment analyses of the key taxon IVs, although these results might be only suggestive rather than confirmed.

First, the single nucleotide polymorphism database (dbSNP) provided by the National Institutes of Health of the United State was utilized to determine the related genes of IVs (https://www.ncbi.nlm.nih.gov/snp/). Then, the tool known as the database for annotation, visualization and integrated discovery (DAVID) provided by the National Institutes of Health of the United States was used to perform gene-enrichment analysis with annotation categories of diseases (from Genetic Association Disease Database) and gene ontology (Huang and Sherman, 2009; Sherman et al., 2022) (https://david.ncifcrf.gov/). The default threshold used is P < 0.1 and count >2.

We attempted to use the enrichment analysis of the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, but it produced no significant results. As an alternative, the transcription factor genes that interact with the products of IV-related genes were first investigated to indirectly explore the possible related molecular pathways. The interacting transcription factors were also investigated using the DAVID tool. Then, the enrichment analysis of KEGG pathways was performed again with the identified transcription factors to ascertain the possible molecular pathways involved (It is worth noting that these indirect results are suggestive and have much weaker power).

Results

Study A: effect of gut microbiota on hypothyroidism

A total of 2,151 SNPs were selected as IVs for 35 families and 130 genera of gut microbiota, which is listed in Supplementary Table S2. Five MR methods mentioned before were performed for each taxon, and all results are displayed in Supplementary Table S3, while the results of tests of heterogeneity and horizontal pleiotropy are listed in Supplementary Table S4. The directions of each pair of taxon and outcome were further confirmed with the Steiger test to avoid reverse causation (Supplementary Table S6).

For easy check, the significant results of primary methods are summarized and displayed in Table 1, while the corresponding results of heterogeneity and horizontal pleiotropy are listed in Supplementary Table S5. The relationships of significant families and genera are shown in Figure 2. The figure shows that two families and two genera can causally inhibit hypothyroidism, while two families and six genera can facilitate hypothyroidism. Only *Defluviitaleaceae* (OR 0.043, 95%CI 0.005–0.363, P = 0.018)/*Defluviitaleaceae_UCG_011* (OR 0.385, 95%CI 0.172–0.865,

P = 0.021) and *Bacteroidaceae* (OR 3.363, 95%CI 1.312–8.617, P = 0.012)/*Bacteroides* (OR 3.363, 95%CI 1.312–8.617, P = 0.012) are significant at both the taxonomical levels.

Although the primary method results of both pairs are significant, more methods of *Defluviitaleaceae* also support significance. Meanwhile, a supplementary of probiotic bacteria is more economical and has higher application value than targeting harmful bacteria. Therefore, the *Defluviitaleaceae* family and *Defluviitaleaceae_UCG_011* genus are selected as key taxa of gut microbiota for further investigation in Study B.

Study B: effect of *Defluviitaleaceae* on causes toward hypothyroidism

In this part, SNPs used as IVs is listed in Supplementary Table S7. All of the MR results in this part are summarized in Supplementary Table S8, while results of tests of heterogeneity and horizontal pleiotropy are listed in Supplementary Table S9. The directions of causation between *Defluviitaleaceae* and outcomes are checked with Steiger test, and there is no reverse causation (Supplementary Table S11). The MR results of outcomes, which contain significant results are listed in Table 2 for easy check, and corresponding results of heterogeneity and pleiotropy are in Supplementary Table S10.

Firstly, variables related to hypothyroidism in FinnGen database are selected as outcome variables to understand the causal effect of *Defluviitaleaceae*. These factors include "thyroiditis," "congenital iodine-deficiency syndrome," "autoimmune hypothyroidism," "postinfectious hypothyroidism," "hypothyroidism due to medicaments and other exogenous," and "other/unspecified hypothyroidism." The results of thyroiditis are significant for both of *Defluviitaleaceae* family (OR 0.174, 95%CI 0.046–0.653, P = 0.029) and *Defluviitaleaceae_UCG_011* genus (OR 0.139, 95%CI 0.029–0.664, P = 0.043) (Figures 3A, B), while no significance is found in other outcome variables.

Then, MR analyses are performed between *Defluviitaleaceae* and three subtypes of thyroiditis in FinnGen database, which are "subacute thyroiditis" (family: OR 0.028, 95%CI 0.004–0.213, P = 0.007; genus: OR 0.018, 95%CI 0.002–0.194, P = 0.013) (Figures 3A, B), "autoimmune thyroiditis" (family: OR 0.982, 95%CI 0.459–2.104, P = 0.964; genus: OR 0.916, 95%CI 0.391–2.146, P = 0.840), and "unspecified thyroiditis" (family: OR 1.401, 95%CI 0.632–3.103, P = 0.406; genus: OR 2.254, 95%CI 0.926–5.487, P = 0.073) (Supplementary Table S8).

Therefore, the association of *Defluviitaleaceae* with mumps (family: OR 0.811, 95%CI 0.460–1.429, P = 0.469; genus: OR 0.791, 95%CI 0.419–1.492, P = 0.468) (Supplementary Table S8) and influenza (family: OR 0.818, 95%CI 0.676–0.989, P = 0.038; genus: OR 0.792, 95%CI 0.644–0.974, P = 0.027) (Figures 3A, B) are further explored, which are the common infections causing subacute thyroiditis. Because there are no summary-level GWAS data of coxsackievirus and adenovirus, the key proteins, coxsackievirus and adenovirus receptor, are analyzed as an alternative (family: OR 0.99,4 95%CI 0.818–1.209, P = 0.956; genus: OR 1.045, 95%CI 0.847–1.289, P = 0.679) (Supplementary Table S8). Although there is no causality found

TABLE 1 The significant causal estimates of gut microbiota with hypothyroidism in MR analyses.

Primary method	N_SNP	Beta	SE	P-value	OR	Lower limit	Higher limit
Inverse variance weighted	9	1.213	0.480	0.012	3.363	1.312	8.617
MR Egger	11	-3.155	1.093	0.018	0.043	0.005	0.363
Inverse variance weighted	10	0.477	0.230	0.038	1.611	1.026	2.529
MR Egger	12	-2.112	0.903	0.042	0.121	0.021	0.711
Inverse variance weighted	11	0.395	0.180	0.028	1.484	1.043	2.112
Inverse variance weighted	8	-0.755	0.321	0.019	0.470	0.251	0.882
Inverse variance weighted	9	1.213	0.480	0.012	3.363	1.312	8.617
Inverse variance weighted	10	0.815	0.413	0.048	2.260	1.007	5.074
Inverse variance weighted	7	0.672	0.302	0.026	1.959	1.085	3.537
Inverse variance weighted	9	-0.954	0.413	0.021	0.385	0.172	0.865
Inverse variance weighted	15	0.624	0.250	0.013	1.866	1.143	3.046
MR egger	10	2.986	1.018	0.019	19.816	2.693	145.812



with coxsackievirus and adenovirus receptor in this study, it needs more direct evidence as proof.

Finally, MR analyses are performed between *Defluviitaleaceae* and antibody level of different subtypes of influenza. A significant increase of H3N2 IgG levels with *Defluviitaleaceae* family (OR 1.934, 95%CI 1.123–3.332, P = 0.017) was observed, while the result with *Defluviitaleaceae_UCG_011* genus is not significant (OR 1.675, 95%CI 0.953–2.943, P = 0.073) but still suggests an increase of the H3N2 antibody level (Figures 3A, B). Both the family and genus fail to find significance with H1N1 antibody level (family: OR 1.260, 95%CI 0.705–2.255, P = 0.435; genus: OR 1.210, 95%CI 0.651–2.249, P = 0.547) (Supplementary Table S8).

In sum, the results of the present study suggest that *Defluviitaleaceae* might be able to increase anti-influenza H3N2 IgG levels to decrease the occurrence of influenza. The decrease of influenza by *Defluviitaleaceae* prevents subacute thyroiditis and hypothyroidism (Figure 3C). Figure 4 shows the significant findings in the form of scatter plots.

As supplementary, forest plots (showing robustness of MR results) and leave-one-out plots (showing any outliers in IVs) of variables are displayed in Supplementary Figures S1, S2.

Exploration of related mechanisms with enrichment analysis

There are 13 different SNPs as IVs of *Defluviitaleaceae*, of which 9 of them have corresponding genes, which are listed

Outcome	Exposure	Primary method	N_SNP	Beta	SE	<i>P</i> value	OR	Lower Limit	Higher Limit
Hypothyroidism	genus.DefluviitaleaceaeUCG011.id.11287	Inverse variance weighted	9	-0.954	0.413	0.021	0.385	0.172	0.865
Hypothyroidism	family.Defluviitaleaceae.id.1924	MR Egger	11	-3.155	1.093	0.018	0.043	0.005	0.363
Thyroiditis	genus.DefluviitaleaceaeUCG011.id.11287	MR Egger	9	-1.973	0.798	0.043	0.139	0.029	0.664
Thyroiditis	family.Defluviitaleaceae.id.1924	MR Egger	11	-1.749	0.675	0.029	0.174	0.046	0.653
Subacute thyroiditis	genus.DefluviitaleaceaeUCG011.id.11287	MR Egger	9	-4.008	1.208	0.013	0.018	0.002	0.194
Subacute thyroiditis	family.Defluviitaleaceae.id.1924	MR Egger	11	-3.587	1.040	0.007	0.028	0.004	0.213
All influenza	genus.DefluviitaleaceaeUCG011.id.11287	Inverse variance weighted	9	-0.233	0.105	0.027	0.792	0.644	0.974
All influenza	family.Defluviitaleaceae.id.1924	Inverse variance weighted	11	-0.201	0.097	0.038	0.818	0.676	0.989
Anti-Influenza virus subtype H3N2 IgG levels	genus.DefluviitaleaceaeUCG011.id.11287	Inverse variance weighted	8	0.516	0.288	0.073	1.675	0.953	2.943
Anti-Influenza virus subtype H3N2 IgG levels	family.Defluviitaleaceae.id.1924	Inverse variance weighted	9	0.660	0.277	0.017	1.934	1.123	3.332

TABLE 2 The significant causal estimates of *Defluviitaleaceae* family and *DefluviitaleaceaeDefluviitaleaceae_UCG_011* genus with hypothyroidism, thyroiditis, sub thyroiditis, influenza, and anti-influenza H3N2 IgG level in MR analyses.

in Table 3A. Since only nine genes were used as input to perform enrichment analysis, the results with P < 0.1 were limited, and all of them are listed in Table 3B. The results show involvement in metabolic and immune fields, specifically with neutrophils, respiratory function tests, celiac disease, lipoproteins, and echocardiography results. In GO analysis, these genes are associated with cell adhesion. Although it is difficult to observe the association between cell adhesion and influenza, thyroiditis, and hypothyroidism, the enrichment results indicating immune system and neutrophils count are consistent with the finding of this study.

Since the nine SNP-related genes failed to find the involved pathway in KEGG pathway enrichment analysis, the transcription factors interacting with them were identified instead, which are listed in Supplementary Table S12A. The KEGG pathways of these transcription factors may give us some hints about the involved molecular pathways. The results can be observed in Supplementary Table S12B. It is worth noting that these indirect results are suggestive and have much weaker power. Since it is the indirect results of interacting transcription factors, the ranges get larger and are involved with the FoxO and JAK-STAT signaling pathway, immunity (e.g., Th17 cell differentiation), viral infection (e.g., measles and viral hepatitis), hormones (e.g., prolactin), metabolism, and cancer. The immunity, viral infection, and hormones are exactly consistent with the findings of the former part of this study.

Discussion

Since the proposal of the "thyroid-gut-axis" concept (Lerner et al., 2017), quite a few studies have investigated the association between gut microbiota and thyroid-related diseases. Previous studies demonstrated that gut microbiota had an effect on thyroid disorders through the absorption of thyroid hormonerelated nutrients, regulating the iodothyronine metabolism by enzymes (Virili and Centanni, 2017; Knezevic et al., 2020). Besides, gut microbiota might affect thyroid autoimmune diseases through interacting with host immune cells and secreting cytokines (Köhling et al., 2017; Shao et al., 2018). In this study, it was found that Defluviitaleaceae/Defluviitaleaceae_UCG_011 were the protective factors for hypothyroidism, while Bacteroidaceae/Bacteroides were risk factors. Moreover, Defluviitaleaceae might prevent hypothyroidism induced by subacute thyroiditis by interacting with influenza.

In the human gut, Frimicutes and Bacteroidetes are the predominant phyla. Bacteroides are essential in the hydrolysis and fermentation of exogenous dietary fiber as well as endogenous mucins. Bacteroides have been realized with less colonization in patients with Grave's diseases (Ishaq et al., 2018). Moreover, the genus is also decreased in the intestines of mice with Grave's ophthalmopathy, which is the progression symptom of Grave's diseases (Masetti et al., 2018). Conversely, research also declared a reduction of Bacteroides in Hashimoto's thyroiditis patient fecal samples (Sawicka-Gutaj et al., 2022). Bacteroides were also



Significant MR results of *Defluviitaleaceae* family and *DefluviitaleaceaeDefluviitaleaceae_UCG_011* genus. (A) The results of *Defluviitaleaceae* family; (B) the results of *DefluviitaleaceaeDefluviitaleaceae_UCG_011* genus; and (C) the results of this study suggest *Defluviitaleaceae* can increase anti-influenza H3N2 IgG levels to inhibit influenza which further prevents from subacute thyroiditis and hypothyroidism.



FIGURE 4

The scatter plots of MR results of *Defluviitaleaceae* family and *DefluviitaleaceaeDefluviitaleaceae_UCG_011* genus. (A, B) The results of hypothyroidism; (C, D) the results of thyroiditis; (E, F) the results of subacute thyroiditis; (G, H) the results of influenza; (I, J) the results of anti-influenza H3N2 IgG levels; (A, C, E, G, I) the results with *Defluviitaleaceae* family as exposure variable; and (A, C, E, G, I) the results with *DefluviitaleaceaeDefluviitaleaceae_UCG_011* genus as the exposure variable.

TABLE 3 The genes related to the instrument variables of Defluviitaleaceae and the significant enrichment analysis of these genes.

A. Instrumental SNPs and corresponding genes						
SNPs	Gene SNPs		Gene			
rs112893842	PTPRD rs540220		LINC01501			
rs1582238	SPAG17 rs55658617		DSCAM			
rs17051335	None	rs72731813	SLC10A7			
rs1908593	CDH20 rs9608282		SPECC1L			
rs28696126	None rs9725395		None			
rs4344384	LOC124902439 rs2892880		None			
rs4677103	LINC00870					
B. Richment analysis of instrumental genes						
Category	Те	<i>P</i> Value				
GAD_DISEASE_CLASS	META	2.72E-02				
GAD_DISEASE_CLASS	IMM	4.05E-02				
GAD_DISEASE	Celiac	2.98E-03				
GAD_DISEASE	Echocard	5.08E-03				
GAD_DISEASE	Neutr	2.85E-02				
GAD_DISEASE	Lipopt	3.75E-02				
GAD_DISEASE	Lipoprote	4.83E-02				
GAD_DISEASE	Respiratory F	7.43E-02				
GOTERM_BP_DIRECT	GO:0007156~homophilic cell adhesion v	4.39E-02				
GOTERM_BP_DIRECT	GO:0007155~	7.97E-03				

 $Defluviitaleaceae Defluviitaleaceae Defluviitaleaceae_UCG_011.$

discovered to be positively associated with anti-thyropreoxidase antibodies and negatively associated with thyroid-stimulating hormone levels (Sawicka-Gutaj et al., 2022; Fenneman et al., 2023). However, one species of Bacteroides, *Bacteroides fragilis*, is abundant in Hashimoto's thyroiditispatients. *Bacteroides fragilis* activates the NLRP3 expression, which is overexpressed in the thyroid tissue of Hashimoto's thyroiditis patients (Gong et al., 2021).

Defluviitaleaceae/Defluviitaleaceae_UCG_011 was discovered by us to inhibit hypothyroidism. As a family in Clostridia, Defluviitaleaceae/Defluviitaleaceae_UCG_011 seem to be a probiotic. Previous studies implied that the abundance of Defluviitaleaceae/Defluviitaleaceae_UCG_011 was reduced in autoimmune-related diseases, such as rheumatoid arthritis, and systemic lupus erythematosus (Tong et al., 2019; Li et al., 2020). In addition, Defluviitaleaceae_UCG_011 might play a protective role to reduce cardiac fibrosis (Du et al., 2022). However, the relationship between Defluviitaleaceae/DefluviitaleaceaeDefluviitaleaceae_UCG_011 thyroid-related and diseases has not been The association investigated. between Defluviitaleaceae/DefluviitaleaceaeDefluviitaleaceae_UCG_011 and different subtypes of hypothyroidism is further explored. Defluviitaleaceae/DefluviitaleaceaeDefluviitaleaceae_UCG_011 was found to be a significantly protective factor for subacute thyroiditis. The potential mechanisms of these microbiota affecting thyroid function have not been investigated earlier. Viral infections including mumps and influenza were frequently regarded as a major cause of subacute thyroiditis (Desailloud and Hober, 2009). It was observed that influenza could cause subacute thyroiditis, such as H1N1 influenza infection (Dimos et al., 2010; Michas et al., 2014). Consistent with the findings of this study, the significant effect of *Defluviitaleaceae* to influenza antibodies was discovered. *Defluviitaleaceae* was likely to prevent subacute thyroiditis and hypothyroidism through influenza. *DefluviitaleaceaeDefluviitaleaceae_UCG_011*.

There have been many probiotics found using which homeostasis can be modeled to prevent from diseases (Mahmud et al., 2022). For Defluviitaleaceae, the results of enrichment analyses in this study indicate that it participates in individuals' metabolism and immunity, which are important fields for homeostasis. In the field of immune system, it is suggested to be associated with neutrophils (Table 3). In another study, Defluviitaleaceae was found to inhibit granulomatosis with polyangiitis through CD11c in granulocytes (Chen and Tang, 2023), most of which are neutrophils, which is consistent with the findings of this study. In addition, the indirect enrichment analyses with related transcription factors in this study (Supplementary Table S12) indicate the suggestive association with multiple viral infections, while influenza is also a viral disease. In the results related to metabolism in this study, Defluviitaleaceae seems to influence celiac disease and lipoproteins. There are

also supporting studies despite which Defluviitaleaceae studies are limited. Cao et al. (2023) proved that Defluviitaleaceae were protective factors for visceral adipose tissue production, while Warbeck et al. (2021) reported that the abundance of Defluviitaleaceae was higher in the treatment group of celiac disease than controls. Although no significant results were found in the enrichment analyses of related genes of IVs, interacting transcription factors in Supplementary Table S12 were investigated as a suggestive reference, in the results of which the FoxO and JAK-STAT pathways are ranked at the top. The JAK-STAT signaling pathway is especially important to the immune system functions, including fighting infection, reinforcing barriers, and even cancer prevention (Hu et al., 2023a). Studies have proven the association between influenza and JAK-STAT signaling (Uetani et al., 2008). In relation to the relationship between JAK-STAT signaling pathway and thyroiditis, there is only one study that mentions the pathway participating in Grave's disease, which is another thyroiditis other than subacute thyroiditis (Li et al., 2024). However, the exploration of the mechanism of Defluviitaleaceae is indicative. More studies are warranted to further understand how Defluviitaleaceae can remodel the homeostasis of people.

As for the main method used in this study, MR is a method used in epidemiology and genetics to explore the causal relationships between modifiable exposures, intermediate factors, and outcomes. However, it can be challenging to explore molecular mechanisms and the potential drug target site if there are no adequate GWAS data. Some advanced prediction algorithms can be helpful for further investigation (Hu et al., 2023b). For example, researchers found a novel geometric deep learning and heterogeneous information network that can not only be useful in drug reposition (Zhao et al., 2022) but also in drug-target interactions (Zhao et al., 2023), which are both important in drug development and translational medicine. In the future, the application of advanced computational algorithms should facilitate an understanding of how Defluviitaleaceae remodels the individuals' homeostasis and contributes to treatment development related to the findings of this study.

There are limitations to this study. First, the summary-level GWAS data used in this study cannot be used to perform stratified analyses by covariates, such as age and sex. Second, the findings of this study are based on two-sample MR methods, which are used to investigate linear causal associations. Any non-linear effects of the gut microbiota on the outcome variables involved in this study are unable to be assessed. Third, the exploration of molecular mechanism in this study is still superficial and might be difficult to extrapolate to other diseases. Further research, especially bacterial studies in vivo, are warranted to validate the findings and further understand how Defluviitaleaceae regulates homeostasis and prevents diseases. Finally, the results only indicate the key role of Defluviitaleaceae family and DefluviitaleaceaeDefluviitaleaceae_UCG_011 genus. Since the data source of the gut microbiota does not include any data of specific bacterial species, in this study, we were unable to explore the effect of different species in DefluviitaleaceaeDefluviitaleaceae_UCG_011 genus. Therefore, further Defluviitaleaceae supplementation trials are needed in the future to verify the relationship between Defluviitaleaceae and the clinical pathway of "Influenza-Subacute Thyroiditis-Hypothyroidism."

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding authors.

Author contributions

XZ: Conceptualization, Formal analysis, Methodology, Writing – original draft. P-HL: Conceptualization, Formal analysis, Methodology, Writing – original draft. DW: Conceptualization, Formal analysis, Methodology, Writing – original draft. HLi: Validation, Writing – review & editing. XK: Validation, Writing – review & editing. GZ: Validation, Writing – review & editing. JL: Validation, Writing – review & editing. WW: Validation, Writing – review & editing. YZhao: YZhan: Funding acquisition, Supervision, Writing – review & editing. Z-HL: Funding acquisition, Supervision, Writing – review & editing. HLu: Funding acquisition, Supervision, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. We received funding from the Sichuan Science and Technology Program (2023YFS0098, 2023YFG0278, and 2023YFS0113); the Clinical Research Incubation Project, West China Hospital, Sichuan University (22HXFH019); the Post-Doctor Research Project, West China Hospital, Sichuan University (2021HXBH054); the Sichuan University postdoctoral interdisciplinary Innovation Fund; the Natural Science Foundation of Sichuan Province (2023NSFSC1851); and China Postdoctoral Science Foundation (2023M732446).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2024. 1354989/full#supplementary-material

References

Bowden, J., and Vansteelandt, S. (2011). Mendelian randomization analysis of case-control data using structural mean models. *Stat. Med.* 30, 678–694. doi: 10.1002/sim.4138

Burgess, S., and Thompson, S. G. (2021). Mendelian Randomization: Methods for Causal Inference Using Genetic Variants. London: CRC Press. doi: 10.1201/9780429324352

Cao, F., Pan, F., Gong, X., Wang, W., Xu, Y., Cao, P., et al. (2023). Causal relationship between gut microbiota with subcutaneous and visceral adipose tissue: a bidirectional two-sample Mendelian Randomization study. *Front. Microbiol.* 14:1285982. doi: 10.3389/fmicb.2023.1285982

Chaker, L., Bianco, A. C., Jonklaas, J., and Peeters, R. P. (2017). Hypothyroidism. Lancet. 390, 1550–1562. doi: 10.1016/S0140-6736(17)30703-1

Chen, J., Wright, K., Davis, J. M., Jeraldo, P., Marietta, E. V., Murray, J., et al. (2016). An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis. *Genome Med.* 8:43. doi: 10.1186/s13073-016-0299-7

Chen, Y., and Tang, S. (2023). Gut microbiota and immune mediation: a Mendelian randomization study on granulomatosis with polyangiitis. *Front. Immunol.* 14:1296016. doi: 10.3389/fimmu.2023.1296016

Desailloud, R., and Hober, D. (2009). Viruses and thyroiditis: an update. Virol. J. 6:5. doi: 10.1186/1743-422X-6-5

Dimos, G., Pappas, G., and Akritidis, N. (2010). Subacute thyroiditis in the course of novel H1N1 influenza infection. *Endocrine*. 37, 440-441. doi: 10.1007/s12020-010-9327-3

Dodd, D., Spitzer, M. H., Van Treuren, W., Merrill, B. D., Hryckowian, A. J., Higginbottom, S. K., et al. (2017). A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites. *Nature*. 551, 648–652. doi: 10.1038/nature 24661

Du, X. Q., Shi, L. P., Chen, Z. W., Hu, J. Y., Zuo, B., Xiong, Y., et al. (2022). Astragaloside IV Ameliorates isoprenaline-induced cardiac fibrosis in mice via modulating gut microbiota and fecal metabolites. *Front. Cell Infect. Microbiol.* 12:836150. doi: 10.3389/fcimb.2022.836150

Eckburg, P. B., Bik, E. M., Bernstein, C. N., Purdom, E., Dethlefsen, L., Sargent, M., et al. (2005). Diversity of the human intestinal microbial flora. *Science*. 308, 1635–1638. doi: 10.1126/science.1110591

Fenneman, A. C., Bruinstroop, E., Nieuwdorp, M., van der Spek, A. H., and Boelen, A. A. (2023). Comprehensive review of thyroid hormone metabolism in the gut and its clinical implications. *Thyroid.* 33, 32–44. doi: 10.1089/thy.2022.0491

Fröhlich, E., and Wahl, R. (2019). Microbiota and thyroid interaction in health and disease. *Trends Endocrinol. Metab.* 30, 479–490. doi: 10.1016/j.tem.2019.05.008

Garmendia Madariaga, A., Santos Palacios, S., Guillén-Grima, F., and Galofré, J. C. (2014). The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J. Clin. Endocrinol. Metab. 99, 923–931. doi: 10.1210/jc.2013-2409

Gencer, B., Collet, T. H., Virgini, V., Bauer, D. C., Gussekloo, J., Cappola, A. R., et al. (2012). Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. *Circulation*. 126, 1040–1049. doi: 10.1161/CIRCULATIONAHA.112.096024

Gill, S. R., Pop, M., Deboy, R. T., Eckburg, P. B., Turnbaugh, P. J., Samuel, B. S., et al. (2006). Metagenomic analysis of the human distal gut microbiome. *Science*. 312, 1355–1359. doi: 10.1126/science.1124234

Gong, B., Wang, C., Meng, F., Wang, H., Song, B., Yang, Y., et al. (2021). Association between gut microbiota and autoimmune thyroid disease: a systematic review and meta-analysis. *Front. Endocrinol.* 12:774362. doi: 10.3389/fendo.2021.774362

Hegedüs, L., Bianco, A. C., Jonklaas, J., Pearce, S. H., Weetman, A. P., Perros, P., et al. (2022). Primary hypothyroidism and quality of life. *Nat. Rev. Endocrinol.* 18, 230–242. doi: 10.1038/s41574-021-00625-8

Hollowell, J. G., Staehling, N. W., Flanders, W. D., Hannon, W. H., Gunter, E. W., Spencer, C. A., et al. (2002). Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): national health and nutrition examination survey (NHANES III). *J. Clin. Endocrinol. Metab.* 87, 489–499. doi:10.1210/jcem.87.2.8182

Hu, L., Yang, Y., Tang, Z., He, Y., and Luo, X. (2023b). FCAN-MOPSO: an improved fuzzy-based graph clustering algorithm for complex networks with multiobjective particle swarm optimization. *IEEE Trans. Fuzzy Syst.* 31, 3470–3484. doi: 10.1109/TFUZZ.2023.3259726

Hu, Q., Bian, Q., Rong, D., Wang, L., Song, J., Huang, H. S., et al. (2023a). JAK/STAT pathway: extracellular signals, diseases, immunity, and therapeutic regimens. *Front. Bioeng. Biotechnol.* 11:1110765. doi: 10.3389/fbioe.2023. 1110765

Huang, D. W., and Sherman, B. T. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat. Protocols* 4, 44–57. doi: 10.1038/nprot.2008.211

Ishaq, H. M., Mohammad, I. S., Shahzad, M., Ma, C., Raza, M. A., Wu, X., et al. (2018). Molecular alteration analysis of human gut microbial composition in graves' disease patients. *Int. J. Biol. Sci.* 14, 1558–1570. doi: 10.7150/ijbs.24151

Jiang, W., Lu, G., Gao, D., Lv, Z., and Li, D. (2022). The relationships between the gut microbiota and its metabolites with thyroid diseases. *Front. Endocrinol.* 13:943408. doi: 10.3389/fendo.2022.943408

Knezevic, J., Starchl, C., Tmava Berisha, A., and Amrein, K. (2020). Thyroidgut-axis: how does the microbiota influence thyroid function? *Nutrients* 12:1769. doi: 10.3390/nu12061769

Köhling, H. L., Plummer, S. F., Marchesi, J. R., Davidge, K. S., and Ludgate, M. (2017). The microbiota and autoimmunity: Their role in thyroid autoimmune diseases. *Clin. Immunol.* 183, 63–74. doi: 10.1016/j.clim.2017.07.001

Kurilshikov, A., Medina-Gomez, C., Bacigalupe, R., Radjabzadeh, D., Wang, J., Demirkan, A., et al. (2021). Large-scale association analyses identify host factors influencing human gut microbiome composition. *Nat. Genet.* 53, 156–165. doi: 10.1038/s41588-020-00763-1

Lerner, A., Jeremias, P., and Matthias, T. (2017). Gut-thyroid axis and celiac disease. Endocr. Connect. 6, R52-r58. doi: 10.1530/EC-17-0021

Li, B. Z., Zhou, H. Y., Guo, B., Chen, W. J., Tao, J. H., Cao, N. W., et al. (2020). Dysbiosis of oral microbiota is associated with systemic lupus erythematosus. *Arch. Oral. Biol.* 113:104708. doi: 10.1016/j.archoralbio.2020.104708

Li, H., Min, J., Yang, Y., Suo, W., Wang, W., Tian, J., et al. (2024). TMEM2 inhibits the development of Graves' orbitopathy through the JAK-STAT signaling pathway. *J. Biol. Chem.* 300:105607. doi: 10.1016/j.jbc.2023.105607

Li, P., Wang, H., Guo, L., Gou, X., Chen, G., Lin, D., et al. (2022). Association between gut microbiota and preeclampsia-eclampsia: a two-sample Mendelian randomization study. *BMC Med.* 20:443. doi: 10.1186/s12916-022-02657-x

Mahmud, M. R., Akter, S., Tamanna, S. K., Mazumder, L., Esti, I. Z., Banerjee, S., et al. (2022). Impact of gut microbiome on skin health: gut-skin axis observed through the lenses of therapeutics and skin diseases. *Gut Micr.* 14:2096995. doi: 10.1080/19490976.2022.2096995

Masetti, G., Moshkelgosha, S., Köhling, H. L., Covelli, D., Banga, J. P., Berchner-Pfannschmidt, U., et al. (2018). Gut microbiota in experimental murine model of Graves' orbitopathy established in different environments may modulate clinical presentation of disease. *Microbiome*. 6:97. doi: 10.1186/s40168-018-0478-4

Michas, G., Alevetsovitis, G., Andrikou, I., Tsimiklis, S., and De Vryonis, E. (2014). Quervain thyroiditis in the course of H1N1 influenza infection. *Hippokratia*. 18, 86–87.

Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., et al. (2010). A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* 464, 59–65. doi: 10.1038/nature08821

Rodondi, N., den Elzen, W. P., Bauer, D. C., Cappola, A. R., Razvi, S., Walsh, J. P., et al. (2010). Subclinical hypothyroidism and the risk of coronary heart disease and mortality. *Jama.* 304, 1365–1374. doi: 10.1001/jama.2010.1361

Round, J. L., and Mazmanian, S. K. (2009). The gut microbiota shapes intestinal immune responses during health and disease. *Nat. Rev. Immunol.* 9, 313–323. doi: 10.1038/nri2515

Sanderson, E., Glymour, M. M., Holmes, M. V., Kang, H., Morrison, J., Munaf,ò, M. R., et al. (2022). Mendelian randomization. *Nat. Rev. Methods Prim.* 2:6. doi: 10.1038/s43586-021-00092-5

Sawicka-Gutaj, N., Gruszczyński, D., Zawalna, N., Nijakowski, K., Muller, I., Karpiński, T., et al. (2022). Microbiota alterations in patients with autoimmune thyroid diseases: a systematic review. *Int. J. Mol. Sci.* 23:13450. doi: 10.3390/ijms232113450

Shao, S., Yu, X., and Shen, L. (2018). Autoimmune thyroid diseases and Th17/Treg lymphocytes. *Life Sci.* 192, 160–165. doi: 10.1016/j.lfs.2017.11.026

Sherman, B. T., Hao, M., Qiu, J., Jiao, X., Baseler, M. W., Lane, H. C., et al. (2022). DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). *Nucl. Acids Res.* 50, W216–w221. doi: 10.1093/nar/gkac194

Song, J., Wu, Y., Yin, X., Ma, H., and Zhang, J. (2023). The causal links between gut microbiota and COVID-19: a Mendelian randomization study. *J. Med. Virol.* 95:e28784. doi: 10.1002/jmv.28784

Sun, B. B., Maranville, J. C., Peters, J. E., Stacey, D., Staley, J. R., Blackshaw, J., et al. (2018). Genomic atlas of the human plasma proteome. *Nature* 558, 73–79. doi: 10.1038/s41586-018-0175-2

Tlaskalová-Hogenová, H., Stěpánková, R., Kozáková, H., Hudcovic, T., Vannucci, L., Tučková, L., et al. (2011). The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. *Cell Mol. Immunol.* 8, 110–120. doi: 10.1038/cmi.2010.67

Tong, Y., Zheng, L., Qing, P., Zhao, H., Li, Y., Su, L., et al. (2019). Oral Microbiota perturbations are linked to high risk for rheumatoid arthritis. *Front. Cell Infect. Microbiol.* 9:475. doi: 10.3389/fcimb.2019.00475

Uetani, K., Hiroi, M., Meguro, T., Ogawa, H., Kamisako, T., Ohmori, Y., et al. (2008). Influenza A virus abrogates IFN-gamma response in respiratory epithelial cells by disruption of the Jak/Stat pathway. *Eur J. Immunol.* 38, 1559–1573. doi: 10.1002/eji.200737045

Vanhaelst, L., Neve, P., Chailly, P., and Bastenie, P. A. (1967). Coronary-artery disease in hypothyroidism. Observations in clinical myxoedema. *Lancet.* 2, 800–802. doi: 10.1016/S0140-6736(67)92235-0

Virili, C., and Centanni, M. (2017). "With a little help from my friends" -The role of microbiota in thyroid hormone metabolism and enterohepatic recycling. *Mol. Cell Endocrinol.* 458, 39–43. doi: 10.1016/j.mce.2017. 01.053

Virili, C., Stramazzo, I., Bagaglini, M. F., Carretti, A. L., Capriello, S., Romanelli, F., et al. (2023). The relationship between thyroid and human-associated microbiota: a systematic review of reviews. *Rev. Endocr. Metab. Disord.* 25, 215–237. doi: 10.1007/s11154-023-09839-9

Vitale, G., Dicitore, A., Barrea, L., Sbardella, E., Razzore, P., Campione, S., et al. (2021). From microbiota toward gastro-enteropancreatic neuroendocrine

neoplasms: are we on the highway to hell? Rev. Endocr. Metab. Disord. 22, 511–525. doi: 10.1007/s11154-020-09589-y

Warbeck, C., Dowd, A. J., Kronlund, L., Parmar, C., Daun, J. T., Wytsma-Fisher, K., et al. (2021). Feasibility and effects on the gut microbiota of a 12-week high-intensity interval training plus lifestyle education intervention on inactive adults with celiac disease. *Appl. Physiol. Nutr. Metab.* 46, 325–336. doi: 10.1139/apnm-2020-0459

Yao, S., Zhang, M., Dong, S. S., Wang, J. H., Zhang, K., Guo, J., et al. (2022). Bidirectional two-sample Mendelian randomization analysis identifies causal associations between relative carbohydrate intake and depression. *Nat. Hum. Behav.* 6, 1569–1576. doi: 10.1038/s41562-022-01412-9

Zhao, B. W., Su, X. R., Hu, P. W., Huang, Y. A., You, Z. H., and Hu, L. (2023). iGRLDTI: an improved graph representation learning method for predicting drugtarget interactions over heterogeneous biological information network. *Bioinformatics* 39:btad451. doi: 10.1093/bioinformatics/btad451

Zhao, B. W., Su, X. R., Hu, P. W., Ma, Y. P., and Zhou, X. (2022). A geometric deep learning framework for drug repositioning over heterogeneous information networks. *Brief. Bioinform.* 23:bbac384. doi: 10.1093/bib/bbac384